Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Promising data could point to new factor H therapy option
March 2017
SHARING OPTIONS:

FREIBURG, Germany—A team of researchers from Greenovation Biotech GmbH, the University of Freiburg and the University of Jena have been able to show full bioactivity of the human complement factor H produced in the Physcomitrella patens moss. It was shown to be able to control complement activation in serum derived from aHUS patients and in a C3G mouse model. Genetic defects in complement regulatory proteins can result in diseases such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathies (C3G) and age-related macular degeneration. Most mutations affect the glycoprotein complement factor H, and while replacement therapy with recombinantly produced factor H is an option, the compound is not yet available for clinical use. The results were published in the Journal of the American Society of Nephrology in a paper titled “Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.